Martin Shkreli Fired As CEO From Different Pharmaceutical Company

Martin Shkreli Fired
Martin Shkreli, infamous for shepherding Turing Pharmaceuticals to a 5,000 percent price increase of an essential drug, was fired from his position as CEO of a different company. Photo: Martin Shkreli/Twitter

WASHINGTON, Dec. 21 (UPI) — Martin Shkreli, infamous for shepherding Turing Pharmaceuticals to a 5,000-percent price increase for an essential drug, was fired on Monday from his position as CEO of a different company.

KaloBios Pharmaceuticals said it “terminated” Shkreli as CEO. The company also said he resigned from his post as a member of its board, NBC News reported. KaloBios, which has a market cap of less than $100 million, has not traded since last Thursday — the day Shkreli was arrested on charges of securities fraud.

Shkreli, 32, was arrested in relation to a firm he founded in 2011, unrelated to the price hike he instituted for Daraprim with Turing Pharmaceuticals. He was released after posting a $5 million bail.

Prosecutors allege he illegally took stock from his biotechnology firm, Retrophin Inc., and used that to pay debts from unrelated business dealings, the Bloomberg report said Thursday. The Retrophin board of directors later sued Shkreli and he was ousted from the company where he served as CEO.

In a related move, the Securities and Exchange Commission, which opened an investigation into Shkreli in 2012, is expected to file a civil complaint against Shkreli for allegedly fraudulently reclassifying a $900,000 equity investment as a loan.

Shkreli is accused of reclassifying an equity investment from his defunct hedge fund, MSMB Capital Management, after it lost millions and made Retrophin pick up the tab as a loan.

In August, Turing Pharmaceuticals acquired Daraprim, often used to treat toxoplasmosis in people with compromised immune systems like AIDS patients, and the company immediately increased the price of the drug. The price increase raised the average treatment costs for patients from about $1,130 a year to $63,000. Certain patients may need to pay up to $634,000 each year for Daraprim treatment.

Although toxoplamosis isn’t considered dangerous in people who are generally healthy, for people who are pregnant or have a weakened immune system, such as AIDS or cancer patients, the effects of the infection can be severe. Daraprim is also used to treat malaria.

The embattled Shkreli received more negative backlash earlier this month when it was revealed he was the buyer of Wu-Tang Clan’s one-of-a-kind album, Once Upon a Time in Shaolin. He paid $2 million for the only issued copy of the album, immediately placed it in a vault and said he “probably won’t listen to it for years.”


Please enter your comment!
Please enter your name here